NCT04999969 2026-02-03
Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours
AstraZeneca
Phase 2 Active not recruiting
Clinical Trials
8 trialsNCT03075527 2026-01-08
A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT05380713 2025-12-29
......SMARTEST Trial......
University Health Network, Toronto
Phase 2 Completed
NCT02899195 2023-07-05
PrE0505
PrECOG, LLC.
Phase 2 Completed
NCT04115111 2023-03-15
Diadem
Mario Negri Institute for Pharmacological Research
Phase 2 Completed
NCT05429866 2023-03-08
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute
Phase 2 Unknown
NCT02592551 2022-09-29
MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma
Baylor College of Medicine
Phase 2 Completed
NCT02588131 2015-10-27
A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1)
Italian Network for Tumor Biotherapy Foundation
Phase 2 Unknown